Ottawa's The Ottawa Hospital haematology programme manages multiple myeloma patients from across Eastern Ontario and Western Quebec. For Ottawa patients in ODB coverage gaps, self-funding, or managing treatment costs privately, Lenalid 25mg provides the same IMiD backbone as brand Revlimid at dramatically reduced cost — supporting the sustained long-term maintenance therapy that produces the best myeloma survival outcomes.
FAQ 1: What is the REMS programme for Lenalidomide and does it apply to generic Lenalid?
FAQ 2: What is the VRd regimen and how central is Lenalid to it?
FAQ 1: What is the REMS programme for Lenalidomide and does it apply to generic Lenalid?In the USA, Lenalidomide is subject to a Risk Evaluation and Mitigation Strategy (REMS) programme called RevAssist — due to its severe teratogenicity (thalidomide-related birth defects risk). This requires all prescribers, pharmacies, and patients to register in the programme, mandatory monthly pregnancy testing for women of childbearing potential, and dual contraception use. In Canada, a similar pregnancy prevention programme exists through Health Canada requirements. For patients accessing generic Lenalid internationally, the underlying safety obligations — contraception, pregnancy testing, avoiding sharing with others — remain critically important regardless of regulatory programme registration. Ottawa physicians prescribing or supervising generic Lenalid use apply all the same safety monitoring protocols they would for brand Revlimid, as the teratogenicity risk is identical.
FAQ 2: What is the VRd regimen and how central is Lenalid to it?
VRd — Bortezomib (Velcade/Bortenat) + Lenalidomide (Revlimid/Lenalid) + Dexamethasone — is considered one of the standard induction regimens for newly diagnosed transplant-eligible multiple myeloma in North America and many global guidelines. Lenalidomide is central to this regimen as the IMiD component — it contributes both direct anti-myeloma activity (inducing myeloma cell apoptosis through cereblon-mediated degradation of transcription factors Ikaros and Aiolos) and immune modulatory effects that enhance NK cell and T cell anti-tumour responses. The combination of Bortezomib's proteasome inhibition, Lenalidomide's IMiD activity, and dexamethasone's direct anti-myeloma and anti-inflammatory effects produces synergistic tumour killing that neither agent achieves alone. Ottawa's haematologists titrate all three components based on patient tolerance and response.
